FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283383256> ?p ?o ?g. }

• W4283383256 endingPage "1857" @default.
• W4283383256 startingPage "1856" @default.
• W4283383256 abstract "Background: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). Aims: The present study is a 3-years follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. Methods: This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. Results: After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with ISS stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. Summary/Conclusion: In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups." @default.
• W4283383256 created "2022-06-25" @default.
• W4283383256 creator A5000602610 @default.
• W4283383256 creator A5000891603 @default.
• W4283383256 creator A5001280366 @default.
• W4283383256 creator A5002260566 @default.
• W4283383256 creator A5003679742 @default.
• W4283383256 creator A5003699463 @default.
• W4283383256 creator A5007508025 @default.
• W4283383256 creator A5007649651 @default.
• W4283383256 creator A5011195007 @default.
• W4283383256 creator A5011614506 @default.
• W4283383256 creator A5012586021 @default.
• W4283383256 creator A5013261825 @default.
• W4283383256 creator A5013619928 @default.
• W4283383256 creator A5014706102 @default.
• W4283383256 creator A5015093827 @default.
• W4283383256 creator A5016021915 @default.
• W4283383256 creator A5016810972 @default.
• W4283383256 creator A5017844916 @default.
• W4283383256 creator A5018088213 @default.
• W4283383256 creator A5018139570 @default.
• W4283383256 creator A5022153283 @default.
• W4283383256 creator A5026692977 @default.
• W4283383256 creator A5026820300 @default.
• W4283383256 creator A5028317224 @default.
• W4283383256 creator A5028453476 @default.
• W4283383256 creator A5029736700 @default.
• W4283383256 creator A5034002775 @default.
• W4283383256 creator A5039851186 @default.
• W4283383256 creator A5042629318 @default.
• W4283383256 creator A5044244099 @default.
• W4283383256 creator A5045579010 @default.
• W4283383256 creator A5046165635 @default.
• W4283383256 creator A5050601860 @default.
• W4283383256 creator A5051231544 @default.
• W4283383256 creator A5052913762 @default.
• W4283383256 creator A5056516697 @default.
• W4283383256 creator A5057444335 @default.
• W4283383256 creator A5058381643 @default.
• W4283383256 creator A5059655934 @default.
• W4283383256 creator A5062777249 @default.
• W4283383256 creator A5065909618 @default.
• W4283383256 creator A5066631109 @default.
• W4283383256 creator A5066814162 @default.
• W4283383256 creator A5070858900 @default.
• W4283383256 creator A5071926851 @default.
• W4283383256 creator A5072657141 @default.
• W4283383256 creator A5072928867 @default.
• W4283383256 creator A5076887118 @default.
• W4283383256 creator A5077919557 @default.
• W4283383256 creator A5078122346 @default.
• W4283383256 creator A5079910766 @default.
• W4283383256 creator A5080733150 @default.
• W4283383256 creator A5082247510 @default.
• W4283383256 creator A5083644983 @default.
• W4283383256 creator A5085216234 @default.
• W4283383256 creator A5085292624 @default.
• W4283383256 creator A5087324886 @default.
• W4283383256 creator A5088390418 @default.
• W4283383256 creator A5088942860 @default.
• W4283383256 creator A5090545311 @default.
• W4283383256 date "2022-06-01" @default.
• W4283383256 modified "2023-10-01" @default.
• W4283383256 title "PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS" @default.
• W4283383256 doi "https://doi.org/10.1097/01.hs9.0000850772.23648.13" @default.
• W4283383256 hasPublicationYear "2022" @default.
• W4283383256 type Work @default.
• W4283383256 citedByCount "0" @default.
• W4283383256 crossrefType "journal-article" @default.
• W4283383256 hasAuthorship W4283383256A5000602610 @default.
• W4283383256 hasAuthorship W4283383256A5000891603 @default.
• W4283383256 hasAuthorship W4283383256A5001280366 @default.
• W4283383256 hasAuthorship W4283383256A5002260566 @default.
• W4283383256 hasAuthorship W4283383256A5003679742 @default.
• W4283383256 hasAuthorship W4283383256A5003699463 @default.
• W4283383256 hasAuthorship W4283383256A5007508025 @default.
• W4283383256 hasAuthorship W4283383256A5007649651 @default.
• W4283383256 hasAuthorship W4283383256A5011195007 @default.
• W4283383256 hasAuthorship W4283383256A5011614506 @default.
• W4283383256 hasAuthorship W4283383256A5012586021 @default.
• W4283383256 hasAuthorship W4283383256A5013261825 @default.
• W4283383256 hasAuthorship W4283383256A5013619928 @default.
• W4283383256 hasAuthorship W4283383256A5014706102 @default.
• W4283383256 hasAuthorship W4283383256A5015093827 @default.
• W4283383256 hasAuthorship W4283383256A5016021915 @default.
• W4283383256 hasAuthorship W4283383256A5016810972 @default.
• W4283383256 hasAuthorship W4283383256A5017844916 @default.
• W4283383256 hasAuthorship W4283383256A5018088213 @default.
• W4283383256 hasAuthorship W4283383256A5018139570 @default.
• W4283383256 hasAuthorship W4283383256A5022153283 @default.
• W4283383256 hasAuthorship W4283383256A5026692977 @default.
• W4283383256 hasAuthorship W4283383256A5026820300 @default.
• W4283383256 hasAuthorship W4283383256A5028317224 @default.
• W4283383256 hasAuthorship W4283383256A5028453476 @default.
• W4283383256 hasAuthorship W4283383256A5029736700 @default.
• W4283383256 hasAuthorship W4283383256A5034002775 @default.
• W4283383256 hasAuthorship W4283383256A5039851186 @default.

• next